Aaron Li

Aaron Li (full name: Weizhi Aaron Li) is a Vice President at Decheng Capital, a global life sciences venture capital firm managing over $2 billion in capital. He joined the firm in September 2018 and currently serves on the boards of Bioheng and PackGene Biotech, both of which are portfolio companies focused on cell and gene therapy.

Prior to Decheng Capital, Aaron was a Consultant at Boston Consulting Group (BCG), where he specialized in the healthcare practice. At BCG, he covered areas including commercial excellence, emerging market strategy, growth strategy, turnaround, M&A strategy, and post-merger integration support. His clients included leading global pharmaceutical companies, medical technology firms, healthcare service providers, and institutional investors. Before BCG, Aaron worked at L.E.K. Consulting, another global management consultancy with deep healthcare expertise.

Aaron holds a Bachelor's degree in Economics from the Shanghai University of International Business and Economics and an MBA from the Tuck School of Business at Dartmouth College. His consulting background in healthcare strategy combined with his venture capital experience gives him a well-rounded perspective on evaluating and supporting life sciences companies across global markets.

Decheng Capital, where Aaron invests, is focused exclusively on the healthcare and life sciences sector. The firm provides capital and strategic support to early-stage life science companies developing revolutionary technologies, as well as growth-stage healthcare companies with strong market presence. Key areas of focus include:

The firm typically invests in Series A through Series C rounds, with average round sizes of $43.3M (Series A), $70.4M (Series B), and $89.9M (Series C). Decheng takes an active role in portfolio companies, providing board-level governance and operational support to help companies scale.

• Biotechnology & Pharmaceuticals: Drug discovery, biologics, cell and gene therapy, and novel therapeutic modalities.
• Medical Devices & Diagnostics: Innovative devices, diagnostic platforms, and healthcare delivery tools.
• Platform Technologies: CRISPR-based gene editing (e.g., Mammoth Biosciences), immune-oncology, and next-generation sequencing.
• Cross-Border Strategy: Decheng maintains a distinctly global approach with offices in Shanghai, Silicon Valley, and New York, investing in companies across the US, China, and globally, with the ability to help portfolio companies navigate the China-US life sciences corridor.